Regeneron Pharmaceuticals (REGN) Net Cash Flow (2009 - 2026)

Regeneron Pharmaceuticals has reported Net Cash Flow for 18 years, with the latest figure at -$152.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 125.22% year-over-year to -$152.2 million; the trailing twelve-month figure through Mar 2026 stood at -$121.2 million (down 125.1% YoY), and the FY2025 full-year result was $634.4 million, up 355.7% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$152.2 million, down from $610.9 million in the prior quarter.
• The five-year high for Net Cash Flow was $809.4 million in Q1 2023, with the low at -$2.0 billion in Q2 2023.
• Average Net Cash Flow over 5 years is $4.4 million, with a median of $96.2 million recorded in 2022.
• Year-over-year, Net Cash Flow sank 4105.47% in 2023 and soared 573.25% in 2025.
• Tracing REGN's Net Cash Flow over 5 years: stood at -$385.4 million in 2022, then jumped by 249.82% to $577.4 million in 2023, then dropped by 17.23% to $477.9 million in 2024, then rose by 27.83% to $610.9 million in 2025, then sank by 124.91% to -$152.2 million in 2026.
• The last three Net Cash Flow figures came in at -$152.2 million (Q1 2026), $610.9 million (Q4 2025), and $497.9 million (Q3 2025), per Business Quant data.

Peer Comparison